跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NL-OMON30550
NL-OMON30550尚未招募2 期

An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis - Salvage Therapy After Previous Treatment in a Visilizumab Study

PDL Biopharma Inc.0 个研究点目标入组 27 人开始时间: 待定最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
2 期
状态
尚未招募
入组人数
27
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99（—）

入选标准

  • •-Previous participation in a visilizumab study of IVSR-UC.
  • •-Disease progression while enrolled in a previous visilizumab study, and subsequent treatment with salvage therapy (see Definitions).

排除标准

  • •Unable to understand the purpose and risks of the study, or unwilling or unable to provide a signed and dated informed consent.
  • •For U.S. sites, unwilling or unable to provide authorization to use protected health information.

研究者

相似试验

进行中（未招募）
不适用
An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis - RESTORE™ SIntravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)MedDRA version: 9.0Level: LLTClassification code 10045365
EUCTR2005-004105-28-GRPDL BioPharma, Inc.300
进行中（未招募）
不适用
An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative ColitisIntravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)MedDRA version: 9.0Level: LLTClassification code 10045365
EUCTR2005-004105-28-NLPDL BioPharma, Inc300
进行中（未招募）
不适用
An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis - RESTORE™ S
EUCTR2005-004105-28-DEPDL BioPharma, Inc.300
进行中（未招募）
不适用
An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis - RESTORE™ S
EUCTR2005-004105-28-FRPDL BioPharma, Inc.300
进行中（未招募）
不适用
An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis.
EUCTR2005-004105-28-GBPDL BioPharma, Inc.300